Effect of cell therapy on biochemical markers of heart failure in patients with coronary heart disease
Abstract
This article provides the information on the intravenous administration of mesenchymal stem cells (MSCs) to patients with heart failure against coronary heart disease. Autologous MSCs were injected intravenously in a dose of 50 million cells. We revealed an increase in ejection fraction up to 38.6 ± 2.3% and 38.2 ± 2.4% by the end of the 12th and the 24th weeks respectively as compared with the initial state (35 ± 2.5%). By the end of the 12-week observation we revealed a statistically significant decrease in BNP levels up to 311 ± 26 pg/ml as compared with the initial 407 ± 35 pg/mL on the one hand, and as compared with the control group indices on the other. By the end of the 24-week observation this trend continued. Lactate level by the end of 12-week observation had been decreased by 4.37 ± 0.28 mmol / L compared to the baseline (5.08 ± 0 26 mmol/l). The cell therapy in combination with the standard medical therapy has a positive effect on the course of heart failure.
About the Authors
N. V. Sergienko
V.K. Gusak Institute of Emergency and Reconstructive Surgery; M. Gorky Donetsk National Medical University
Russian Federation
Russian Federation
E. N. Naletova
M. Gorky Donetsk National Medical University
Russian Federation
Russian Federation
References
1. Кудряшев В.Э., Иванов С.В., Белецкий Ю.В. Количественная оценка нарушений кровообращения (пробы с физической на-грузкой) - М. : Медицина, 2000. - 224 с.
2. Ahmad T., Fiuzat M., Felker G.M., O'Connor C. Novel biomarkers in chronic heart failure// Nature Reviews Cardiology. - 2012. - Vol. 9, N 6. - Р.347-359.
3. Desai A.S. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are not useful in heart failure management: the art of medicine remains long // Circulation. - 2013. - Vol. 127. - P.509-516.
4. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, 2012 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology [Электронный ресурс] // European Heart Journal. - Режим доступа: https://www.nvvc.nl/media/richtlijn/146, свободный (03.11.13).
5. Hare J.M. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial // JAMA. - 2012. - Vol. 308, N 22. - P. 2369-2379
6. Horwitz E.M. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement // Cytotherapy. - 2005. - Vol.7, № 5. - P. 393-395.
7. Januzzi J.L. Jr., Rehman S.U., Mohammed A.A. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction // J. Am. Coll. Cardiol. - 2011. - Vol. 58, N 18. - P. 1881-1889
8. Jeevanantham V. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis // Circulation. - 2012. - Vol. 126. - P.551-568.
9. Judkins M. P. Selective coronary arteriography. I. A percutaneous transfemoral technic // Radiology. - 1967. - Vol.89, N 5. - P. 815-824.
10. Ky B., French B., Levy W.C. Multiple biomarkers for risk prediction in chronic heart failure // Circulation: Heart Failure. - 2012. - N 5. - P.183-190.
11. Leri A., Anversa P. Stem cells: bone-marrow-derived cells and heart failure-the debate goes on // Nature Reviews Cardiology. - 2013. - № 10. - P.372-373.
12. Patel A.N. Francisco S., Winters A.A. Stem cells therapy for heart failure // Heart Failure Clinics. - 2015. - Vol. 11. - P. 275-286
13. Petrin E.C., Willerson J.T., Pepine C.J. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial // JAMA. - 2012. - Vol. 307, N 16. - P. 1717-1726.
14. Porapakkham P., Porapakkham P., Zimmet H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis // Archives of Internal Medicine. - 2010. - Vol. 170, N 6. - P. 507-514.
15. Rector T.S., Kubo S.H., Cohn J.N. Patients' self-assessment oftheir congestive heart failure. Part 2: Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire// Heart Failure. - 1987. - Vol. 3. - Р. 198-209.
16. Secunda R. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study // Cytotechnology. - 2015. - Vol. 67, N 5. - P. 793-807.
17. Tang Y.L., Wang Y.J., Chen L.J., Pan Y.H., Zhang L., Weintraub N.L. Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications // Experimental Biology Medicine (Maywood). - 2013. - Vol. 238, N 3. - P. 294-300.
18. Troughton R.W., Frampton C.M., Nicholls M.G. Biomarker-guided treatment of heart failure: still waiting for a definitive answer // J. Am. Coll. Cardiol. - 2010. - Vol. 56. - P. 2101-2104.
19. Watson N.C., Heard O.S. The use of lactate as a biomarker // J. Intensive Care Med. - 2010. - Vol. 25, N 5. - P. 301-302.
Review
For citations:
Sergienko N.V., Naletova E.N. Effect of cell therapy on biochemical markers of heart failure in patients with coronary heart disease. Kursk Scientific and Practical Bulletin "Man and His Health". 2016;(1):50-56. (In Russ.)
Views:
517
Email this article 